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Abstract
Medetomidine (0.03 mg/kg) and medetomidine/ketamine (0.05/5.0 and 0.025/2.5 mg/kg), administered by intravenous
injection, were evaluated for short-term immobilization of wild-caught variable flying foxes (Pteropus hypomelanus).
Medetomidine alone produced incomplete chemical restraint and a stressful, prolonged induction. Both ketamine/
medetomidine doses produced a smooth induction and complete immobilization. The combined medetomidine/ketamine
dose of 0.025/2.5 mg/kg produced a rapid induction (2326224 sec) with minimal struggling and vocalization, a complete
and effective immobilization period, and tended to lead to a faster and better quality recovery than medetomidine alone or
a higher dose of medetomidine and ketamine (0.05/5.0 mg/kg), thus reducing holding time and permitting an earlier
release of the bat back into the wild.
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Introduction
The variable flying fox, Pteropus hypomelanus, is an old world fruit
bat and member of a family Pteropididae, which includes many
threatened and endangered species [1,2]. Flying foxes (Pteropus spp.)
have been identified as reservoirs for several important zoonotic
diseases including Hendra virus (HeV), Australian bat lyssavirus
(ABLV), and Nipah virus (NiV) [3,4,5]. Disease surveillance in
flying foxes has consequently increased in response to public
health and economic concerns. Non-destructive epidemiologic
studies of individual pteropid bats require the safe collection of
biological samples from the bat, which frequently include blood
and swabs from the throat, urethra, and rectum [3,6,7,8].
Chemical restraint minimizes the animal’s stress and protects the
researcher during sample collection [9]. A limited number of
injectable anesthetic protocols have been described for pteropid
bats. A combination of acepromazine (1.1 mg/kg) and ketamine
(11 mg/kg) has been used to restrain the Indian flying fox (P.
giganteus) [10], xylazine/ketamine (2/10 mg/kg IM) and medeto-
midine/ketamine (0.03/3–0.06/6 mg/kg IM) has been used in
captive variable flying foxes (P. hypomelanus) [11,12]. Likewise, few
injectable protocols have been described in free-ranging pteropid
bats [10,11,12,13,14].
Optimal anesthesia in situ includes rapid, smooth induction with
a complete immobilization period that is sufficient in duration and
quality for sample collection; provides a smooth, rapid and
uneventful recovery, and ultimately, the safe release of the bat
back to the environment. The purpose of this study was to test
anesthetic protocols that had previously been used on captive P.
hympomelanus [12] on wild bats, and assess the efficacy of
medetomidine alone and medetomidine/ketamine combinations
as chemical restraint agents for the purpose of minimally invasive
clinical sample collection. This report describes the use of
medetomidine and medetomidine/ketamine for the short-term
field immobilization of free-ranging variable flying foxes.
Materials and Methods
Animals
Ethics Statement: The methods used in this project (described
below) were approved by Wildlife Trust’s IACUC, #04-08.
Fifty-two variable flying foxes (Pteropus hypomelanus) were
captured as part of an epidemiologic study of Nipah virus. The
bats were anesthetized and blood, throat, urogenital, and rectal
swabs; and wing punch biopsies were collected from each bat.
Four juveniles were not anesthetized, as they were docile enough
to restrain manually. Additionally, 3 bats (07130435 and
07130413 and 07130433) were excluded from the analysis for
the following reasons: one had no weight recorded, one was given
an initial dose that was not consistent with the protocol and one
was not given IV anesthetic. One bat (7140142) was included in
the anesthesia failure test, but not in the induction time test
because induction time was not recorded. Health status was
assessed based on physical exam and a body condition score and
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sexual characteristics and dental wear [15].
Drugs
Commercial preparations of medetomidine HCl (1 mg/ml,
Dormitor, Pfizer, Pfizer Animal Health, New York, New York
10017) and ketamine HCl (100 mg/ml; Ketaset, Fort Dodge
Laboratories Inc., Fort Dodge, Iowa 50501, USA) were used.
AtipamezoleHCl(5 mg/ml,Antisedan,Pfizer,PfizerAnimalHealth,
New York, New York 10017) was used to reverse medetomidine in
twenty-nine individuals. Bats receiving medetomidine alone were
induced with a dose based on recommendations for rats and rodents
(0.3 mg/kgIM)[16].Batsreceivedinitialdosesbetween0.05 mgand
0.45 mg of medetomidine. The bats from this group that remained
immobilized for the entire sampling procedure (n=4) received an
equivalent volume of atipamezole as a reversal agent. Equal volumes
of medetomidine and ketamine were combined within three hours of
use to make the following concentration: 0.5 mg/ml medetomidine
and 50 mg/ml ketamine. This concentration of medetomidine and
ketamine was used to give one of two doses: either 0.5 mg/kg
medetomidine and 5 mg/kg ketamine or half of that dose 0.25 mg/
kg medetomidine and 2.5 mg/kg ketamine. The bats from this group
that remained immobilized for the entire sampling procedure (n=25)
received a dose of atipamezole equivalent to half of the total
medetomidine volume administered. The anesthetic doses were
administered intravenously (IV) in the cephalic (‘‘patagial’’) vein
located along the cranial edge of the wing membrane between the
shoulder and first digit. Atipamezole was administered intramuscu-
larly (IM) in the pectoralmuscle. All injectionswere given with a 1 ml
syringe and a 1 inch 22 g needle.
Experimental protocol
All bats were caught on Tioman Island, Malaysia
(2u50940.560N, 104u9934.680E) using mist nets between 0400
hr and 0730 hr and again between 1800 hr and 2100 hr [17].
Bats were removed from the net and placed separately into pre-
weighed drawstring cotton pillowcases that were suspended from
tree branches or a rope strung between two trees. During the
day, the pillowcases were hung in the shade. All bats were
weighed in the pillowcase using a digital fishing scale accurate to
0.01 g (Rapala, USA, www.rapala.com). Of the 45 bats in the
study, eleven received medetomidine alone, 18 received the
medetomidine/ketamine dose of 0.05/5.0 mg/kg, and 16 bats
received the medetomidine/ketamine dose of 0.025/2.5 mg/kg.
After injection, each bat was manually restrained with covered
eyes until the animal was anesthetized. Heart rate, respiratory
rate, and body temperature were recorded at the time of
injection and every five minutes until the end of immobilization.
The withdrawal reflex was assessed by manually pinching a
pedal distal phalanx, palpebral reflex by touching the medial
canthus of the eye, and biting reflex was assessed by placing a
metal forceps at the commissure of the lips. Induction time was
defined as the time elapsed from injection of anesthetic to the
loss of withdrawal, palpebral, and biting reflexes. Recovery time
was defined as the time elapsed from the injection of atipamezole
to the time the animal had regained all of its reflexes. Animals
that did not receive atipamezole were not included in the
recovery time assessment. Animals that did not become
anesthetized after receiving one or two doses of their drug
protocol were considered an anesthetic failure event. Following
recovery, the bats were offered mango juice orally via syringe to
provide additional fluids and energy, and then were released at
the site of capture.
Statistical analysis
A chi-square test was used to compare anesthetic failure rate of
the three protocols. Based on the initial results, the two successful
medetomidine/ketamine protocols were compared using a chi-
square test to assess whether one protocol required significantly
more doses of anesthetic. The mean induction and recovery times
were calculated 6 the standard deviation and were compared
using the Mann Whitney U test. A Fisher’s exact test was used
when sample sizes were too low (less than five observations per cell)
for a chi-square. A p-value of ,0.05 was considered significant.
Results
Forty-five animals were included in the analysis (seven juvenile
and 14 adult males; three juvenile and 21 adult females).
Medetomidine alone produced an adequate plane of anesthesia
in 55% (6/11) animals, while medetomidine/ketamine doses of
0.05/5.0 mg/kg and medetomidine/ketamine doses of 0.25/
2.5 mg/kg produced anesthesia in 100% of animals (18/18 and
16/16 respectively). Medetomidine alone was significantly more
likely to fail than either medetomidine/ketamine protocol at
producing anesthesia (Pearson x
2 coefficient: 17.4, p,.001).
There was no significant difference in induction time between
the two medetomidine/ketamine doses (U=91, p=0.12) nor the
number of bats requiring multiple doses to induce anesthesia (x
2
coefficient: 2.6, p=0.13). However, it is likely that with larger
sample sizes a significant difference will be observed as the 0.5/
5.0 mg/kg medetomidine/ketamine dose group had a mean
induction time of 156 seconds and 1/18 (5.6%) of animals needed
an additional dose of anesthesia and the 0.25/2.5 mg/kg
medetomidine/ketamine dose group had a mean induction time
of 232 seconds and 4/16 animals (25%) required additional doses
to induce complete anesthesia. There was a trend that bats
receiving the 0.25/2.5 mg/kg medetomidine/ketamine dose
recovered faster (384 sec) than those receiving the 0.5/5 mg/kg
medetomidine/ketamine dose (759 sec) but this was not significant
(U=29.5, p=0.76). The above results are summarized in Table 1.
Discussion
Medetomidine is an attractive injectable chemical immobiliza-
tion agent when inhalant anesthesia is not available because of its
portability, stability at tropical temperatures, wide therapeutic
index (in dogs) and ability to be rapidly and completely reversed by
atipamezole [16]. It has been used either alone or in combination
as an immobilization agent in other domestic or wildlife species
[18,19]. However, in wild-caught flying foxes, medetomidine
alone is not sufficient to produce complete immobilization for the
purpose of collecting clinical samples such as blood or oral, rectal,
or urogentital swabs. Although 55% of animals induced with
medetomidine alone were adequately immobilized and had a
quick and uneventful recovery when reversed with atipamezole,
45% of animals were not satisfactorily anesthetized. Incomplete
immobilization poses a risk of injury to the handler and increased
stress to the animal. If non-invasive procedures are undertaken,
such as morphometric measurement, weighing, and banding,
medetomidine may be a suitable short-term agent for an
experienced field scientist with a competent technician. However,
more extensive or invasive sampling (blood collection, throat,
rectal, urogenital swabbing, and wing-punch biopsy) that may
cause the animal discomfort or stimulate a sedated bat requires
more complete anesthesia and immobilization. In this study, stress
or excitement from capture and handling may have contributed to
the higher anesthetic failure rate associated with the use of
Medetomidine and Medetomidine/Ketamine in Pteropus
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variable flying foxes that were classified as having experienced an
anesthetic failure, mechanical or auditory stimulation appeared to
decrease the level of sedation achieved when medetomidine was
used alone. This is a known effect in dogs and other wildlife
sedated with medetomidine [9,16]. Bats sedated with medetomi-
dine alone also displayed brief excitatory periods prior to sedation
as evidenced by vocalization, wing flapping, and biting. Because of
concerns of physical injury to the bat or handler, as well as the
potential for zoonotic disease transmission via a bite wound, we
elected to discontinue the trial of medetomidine alone.
Both doses of medetomidine/ketamine produced complete
short-term immobilization in these variable flying foxes, and
higher quality immobilization (sufficiently rapid and smooth
induction, complete plane of anesthesia, and smooth recovery)
compared to medetomidine alone. This allowed for maximal
handler and bat safety. When the medetomidine was reversed in
bats given either medetomidine/ketamine combination, recovery
occasionally involved compulsive movements, including biting,
wing-chewing and wing-flapping; this is consistent with adverse
effects reported in a variety of species when ketamine alone is used
to produce anesthesia [16].
While both dosages of medetomidine/ketamine provided
excellent induction and immobilization, the quality and speed of
recovery was better for bats receiving the 0.025/2.5 mg/kg dose
compared to 0.5/5 mg/kg of medetomidine/ketamine. A trend
toward prolonged recovery times at the higher dose of medeto-
midine/ketamine may be due to a higher dose of ketamine
remaining in the system when the medetomidine was partially
reversed.
Heard et. al. [12] recommended a dose of 0.5/5 mg/kg of
medetomidine/ketamine for immobilization for longer than
30 minutes and found that a dose of 0.03/3 mg/kg has a mean
immobilization time of 18 minutes. However, in the field most
sampling can be conducted within 15 minutes; therefore a lower
dose such as the 0.025/2.5 mg/kg dose could be sufficient and
would still provide a smooth and fast recovery. While the higher
dose of 0.05/k mg/kg medetomidine/ketamine certainly produces
a satisfactory anesthetic plane for very short field procedures it
may not be the ideal protocol for the type of restraint described in
this study, as the use of atipamezole would reverse the
medetomidine but the ketamine would remain biologically active
and at sufficient levels to likely lead to the spastic movements and
prolonged recovery time that our field team noted. Finally, the
induction times in our study are longer than those reported by
Heard et. al.; this most likely because the animals in this study were
stressed free-ranging flying foxes that were trapped, whereas the
study by Heard et. al. used captive animals that were habituated to
periodic capture and handling [12]. Although the 0.25/2.5 mg/kg
dose had a stable anesthetic plane and quick recovery, a quarter of
the animals did require additional doses of anesthetics to be
induced, suggesting that a slightly higher dose of 0.3/3 mg/kg
medetomidine/ketamine protocol may be more efficient and still
minimize the occurrence of prolonged recoveries.
Two pups weighing less than 200 g were immobilized with the
0.5/5 mg/kg dose of medetomidine/ketamine. In both animals,
induction was smooth and immobilization was complete. Howev-
er, recovery of the bat pups was extremely prolonged (9 and
18 minutes) and one became extremely hypothermic (93.8uF).
Ultimately, we recommend not to chemically immobilize pups
given their docile nature, and the ability to safely obtain samples
with physical restraint alone.
In conclusion, of the dosages investigated in this study, we
recommend a medetomidine/ketamine dose of 0.025/2.5 mg/kg,
administered by intravenous injection, for short-term chemical
field immobilization of free-ranging variable flying foxes. A higher
dose is safe in these bats, however the 0.5/5 mg/kg dose maintains
anesthesia for a period longer than necessary for the activities
described in this report, often leading to a prolonged recovery
when the medetomidine is reversed. We do not recommend the
use of medetomidine alone as this protocol failed to produce
adequate restraint nearly 50% of the time.
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